Sapna Pradyuman Patel

52PUBLICATIONS
300CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (52)

|Jul 13, 2026
Decitabine reverses innate immune gene suppression in rare melanomas.

|Jun 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

|Apr 21, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.

|Apr 21, 2026
Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study.

|Jan 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.

Kari L Kendra, Shay L Bellasea, Zeynep Eroglu

|Jul 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.

Elizabeth M Burton, Denái R Milton, Michael T Tetzlaff

Pageof 9

Frequent Collaborators

17 joint publications

Michael A Davies

15 joint publications

Hussein A Tawbi

10 joint publications

Isabella C Glitza Oliva

9 joint publications

Jennifer McQuade